:be Aktie 113268981 / AT0000A2SGH0
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
|
04.09.2025 10:09:00
|
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching closer to that milestone. AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Abbott Laboratories (NYSE: ABT) are among the largest.These healthcare leaders are well-established dividend payers -- all three are in the exclusive group of Dividend Kings that have increased their dividend for at least 50 years -- but can they deliver the kinds of returns they need through the next decade to hit a $1 trillion valuation? Let's find out.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool